Overview: DQ2/DQ8 Haplotypes TestIntroduction: The DQ2/DQ8 Haplotypes Test tests for HLA-DQ2/DQ8 genes to assess risk for celiac disease, causing digestive issues or fatigue, helping guide dietary management. Affecting 1 in 100 people, celiac disease poses diagnostic challenges due to gluten-related symptoms. Following 2023 American College of Gastroenterology (ACG) guidelines, it uses PCR for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, risk assessment, and improving outcomes in gastroenterology.
Other Names: Celiac Risk Test, HLA-DQ2/DQ8 Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: HLA testing began in the 1970s with research by Stokes, who linked DQ2 to celiac disease. PCR advancements in the 1990s by Roche improved detection, surpassing earlier serology methods.
Purpose: Detects DQ2/DQ8 haplotypes to assess celiac risk, guides gluten-free diet, and evaluates patients with digestive issues, aiming to prevent complications.
Test Parameters: DQ2/DQ8 haplotype presence
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of digestive issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document digestive issues or fatigue. Include current medications or gluten exposure.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., malnutrition), and sample collection risks.
Procedural Considerations: Uses PCR to detect haplotypes, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive haplotypes indicate risk, guiding diet. Early management might prevent damage, while untreated cases lead to complications. Negative results may require biopsy.
Specialist Consultation: Consult a gastroenterologist for interpretation.
Additional Supporting Tests: Tissue transglutaminase IgA, endomysial antibody, or biopsy to confirm diagnosis.
Test Limitations: Indicates risk only; correlation with symptoms needed. Negative result does not exclude celiac disease.
References: ACG Guidelines, 2023; Gastroenterology, Stokes PL, 2022.
